Table 1 Test group: Univariate analysis of pre-treatment factors and the radiation regimen for survival
Survival | Survival | Median | p-value | |
|---|---|---|---|---|
at 6 months (%) | at 12 months (%) | survival time (months) | ||
Age | ||||
≤ 64 years | 28 | 15 | 3 | |
≥ 65 years | 30 | 15 | 4 | 0.50 |
Gender | ||||
Female | 32 | 29 | 4 | |
Male | 27 | 10 | 4 | 0.13 |
ECOG Performance status | ||||
1-2 | 51 | 26 | 6 | |
3-4 | 15 | 7 | 3 | <0.001 |
Number of involved vertebrae | ||||
1-2 | 44 | 28 | 4 | |
≥ 3 | 19 | 4 | 3 | <0.001 |
Ambulatory status prior to RT | ||||
Not Ambulatory | 12 | 7 | 2 | |
Ambulatory before RT | 44 | 21 | 5 | <0.001 |
Other bone metastases | ||||
No | 45 | 30 | 4 | |
Yes | 19 | 4 | 3 | <0.001 |
Visceral metastases | ||||
No | 56 | 38 | 9 | |
Yes | 15 | 3 | 3 | <0.001 |
Interval from cancer diagnosis to radiotherapy of MSCC | ||||
≤ 15 months | 26 | 13 | 3 | |
> 15 months | 40 | 23 | 5 | 0.16 |
Time developing motor deficits | ||||
1-7 days | 12 | 4 | 2 | |
> 7 days | 40 | 22 | 5 | <0.001 |
Radiation regimen | ||||
Short-course radiotherapy | 24 | 10 | 3 | |
Longer-course radiotherapy | 32 | 18 | 4 | 0.12 |